Comerica Bank Has $25.18 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Comerica Bank reduced its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 272,635 shares of the biopharmaceutical company’s stock after selling 14,039 shares during the period. Comerica Bank’s holdings in Gilead Sciences were worth $25,183,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. HHM Wealth Advisors LLC raised its stake in Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 154 shares during the last quarter. YANKCOM Partnership acquired a new position in shares of Gilead Sciences during the fourth quarter valued at about $28,000. Decker Retirement Planning Inc. bought a new stake in shares of Gilead Sciences in the fourth quarter valued at about $29,000. Crews Bank & Trust acquired a new stake in Gilead Sciences during the fourth quarter worth about $31,000. Finally, Stephens Consulting LLC increased its stake in Gilead Sciences by 325.0% during the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 260 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

Shares of GILD stock opened at $106.54 on Thursday. The firm’s 50 day moving average price is $109.00 and its two-hundred day moving average price is $98.58. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $119.96. The stock has a market cap of $132.66 billion, a PE ratio of 287.95, a PEG ratio of 0.71 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping analysts’ consensus estimates of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The business had revenue of $6.67 billion during the quarter, compared to analysts’ expectations of $6.77 billion. During the same period in the previous year, the firm earned ($1.32) earnings per share. The firm’s quarterly revenue was down .3% compared to the same quarter last year. As a group, analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be paid a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.97%. The ex-dividend date is Friday, June 13th. Gilead Sciences’s payout ratio is 66.53%.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. Piper Sandler raised their price objective on Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 12th. BMO Capital Markets lifted their price objective on Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a report on Wednesday, February 12th. DZ Bank raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 target price for the company in a report on Thursday, February 13th. Bank of America boosted their price target on Gilead Sciences from $116.00 to $126.00 and gave the company a “buy” rating in a research note on Wednesday, March 5th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research report on Friday, April 25th. Nine equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $109.43.

Insider Activity at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 137,676 shares of the firm’s stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $102.22, for a total transaction of $14,073,240.72. Following the sale, the chief financial officer now owns 171,223 shares of the company’s stock, valued at $17,502,415.06. This trade represents a 44.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last 90 days, insiders sold 302,785 shares of company stock worth $30,540,875. 0.27% of the stock is currently owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.